Description

This session will provide attendees with information about new research in radiopharmaceuticals to evaluate dementia and with information about the use of molecular brain imaging in clinical trials of anti-Alzheimer's therapies. Attendees will develop a better understanding of the regulatory processes leading to translation of amyloid-binding radiopharmaceuticals into the clinic. This information will help attendees make their facilities referral sites for amyloid imaging in clinical trials. 

Subspecialties: MI, NU
Modalities: NM

Speaker(s):

• Kirk Frey, MD, PHD
• Peter Herscovitch, MD
• Satoshi Minoshima, MD, PhD
• John Seibyl, MD

Disclosures

• Satoshi Minoshima, MD, PhD : Consultant: Hamamatsu Photonics; Royalty Income: GE Healthcare; Research Grants: Hitachi Medical Corp, Phillips Healthcare, Nihon Medi Physics, Seattle Genetics, Astellas Pharma
• Kirk Frey, MD, PHD : Consultant: MIM Software Inc, Bayer Healthcare, Avid Radiophamraceuticals; Research Grants: GE Healthcare 
• John Seibyl, MD : Ownership/Partnership: Molecular Neuroimaging, LLC -equity